Hallucinations. Sleep paralysis. Excessive daytime sleepiness. Jenny Lee-Gilmore was diagnosed with Type 1 narcolepsy at 21 — seven years after she first went to a doctor about her symptoms. This is ...

The narcolepsy treatment market is projected to grow from USD 5,301.6 million in 2024 to USD 8,718.3 million by 2034, at a ...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment. The milder form of narcolepsy includes symptoms of excessive ...

Various medications that treat narcolepsy are available, and treatment plans can vary based on individual symptoms and other ...

The FDA has expanded the approval of Lumryz (sodium oxybate) extended-release oral suspension to include treatment of pediatric narcolepsy.

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda ...

It was a huge relief to be diagnosed with narcolepsy, because I was able to finally say this is the problem. And this is what I need to resolve the problem. Treatment has been life-changing.

Get inspired by a weekly roundup on living well, made simple. Sign up for CNN’s Life, But Better newsletter for information ...

Avadel Pharmaceuticals expects its narcolepsy treatment Lumryz to drive strong revenue growth in the fourth quarter and into 2025, preliminary earnings show.

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...

Avadel said it expects Lumryz to generate about $50 million in revenue for the fourth quarter, missing current analyst forecasts by $3.7 million, and $169 million for the full year, $1.7 million shy ...

Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces today that it has acquired at the end ...